Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

APRINOIA Therapeutics

Request full access

Dedicated to development of imaging-based diagnostic tools to improve the detection of occurrence, progression, and regression of neurological diseases

Taipei, TaiwanFounded 2015Biotech & Life Sciences

About APRINOIA Therapeutics

APRINOIA Therapeutics is a clinical-stage biotechnology company focused on discovering and developing diagnostics and therapeutics for Alzheimer's Disease (AD) and other tau-associated neurodegenerative diseases, known as tauopathies. The company operates in the healthcare and biotechnology market, serving patients, research institutions, and pharmaceutical companies. APRINOIA's business model involves building comprehensive internal drug discovery and development capabilities, as well as forming integrative collaborations with world-class scientists and research institutions. The company generates revenue through licensing agreements, such as its non-exclusive licensing agreement with Celgene Corporation for the use of its novel investigational PET imaging tracer, APN-1607. APRINOIA's pipeline includes diagnostic imaging tracers, monoclonal antibodies (mAbs) specific to pathologic tau, and small molecules that bind to tau. The company aims to develop imaging biomarkers to visualize therapeutic targets and subsequently create treatments to address these targets.

Source: Dealroom company data

At a glance

Status
Listed
Listing
Public via SPAC 2023
Employees
22
Open positions
None listed
Dealroom signal
74.4/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Drug Development, Health Diagnostics, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
POST IPO EQUITY✓Other financing Feb 2024 $50M — Undisclosed ↗
GRANT✓Other financing Sep 2023 $4.4M — Alzheimer's Drug Discovery Foundation ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

APRINOIA Therapeutics website traffic

Latest recorded traffic for APRINOIA Therapeutics is 660 monthly website visits, down 83.5% over the last three months. APRINOIA Therapeutics's team grew 4.8% over the past year.

Latest monthly visits660 3-month web change-83.5% 1-year team growth+4.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

APRINOIA Therapeutics in the Taipei ecosystem

Live from Dealroom

The APRINOIA Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

10 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Michael J. Fox Foundation for Parkinson's Research
  • Alzheimer's Drug Discovery Foundation

Series A2 investors entered at this stage

  • Daol Investment (Formerly KTB Network)
  • Daiwa Corporate Investment

Series B and later3 investors entered at this stage

  • Yantai Dongcheng Pharmaceutical
  • IMM Private Equity
  • Ross Acquisition Corp II

Other known investors3 additional known investors

  • National Institutes for Quantum Science and Technology
  • Company K Partners
  • ShangPharma Innovation
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇺🇸 United States46.1%
🇯🇵 Japan7.7%
🇹🇼 Taiwan7.7%
🇨🇳 China7.7%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about APRINOIA Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See APRINOIA Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.